Neurocrine Biosciences (NBIX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Neurocrine Biosciences (NBIX) is Neutral.

The composite score behind that read is +0.13, weighing +0.29 of bullish evidence against -0.17 bearish.

Neurocrine Biosciences last closed at $142.44, +0.84% on the session.

Against the IVW growth benchmark the position is +0.04% over the forecast window.

The read is built from 15 underlying insights — 9 bullish and 6 bearish.

Agreement across those insights is 60%.

1 graded prediction for NBIX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Neurocrine Biosciences in the 45th percentile on valuation and the 81st percentile on return on equity, where 100 is best.

Neurocrine Biosciences is classified under Health Care / Biotechnology, with a market capitalisation of $14.36B.

StockMap tracks Neurocrine Biosciences as the 20th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Neurocrine Biosciences ranks 37th of 381 in the group, against a group median of -0.08.